ValuEngine upgraded shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) from a strong sell rating to a sell rating in a research report sent to investors on Wednesday.
A number of other analysts have also recently commented on AXSM. Aegis restated a buy rating and issued a $20.00 price target on shares of Axsome Therapeutics in a research report on Thursday, May 25th. Zacks Investment Research raised Axsome Therapeutics from a hold rating to a buy rating and set a $4.75 price objective for the company in a research note on Wednesday, May 24th. BTIG Research began coverage on Axsome Therapeutics in a research note on Friday, May 19th. They issued a buy rating and a $14.00 price objective for the company. Finally, Cantor Fitzgerald set a $13.00 price objective on Axsome Therapeutics and gave the stock a buy rating in a research note on Wednesday, March 8th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $14.30.
Shares of Axsome Therapeutics (AXSM) remained flat at $5.25 during trading on Wednesday. The company’s stock had a trading volume of 31,352 shares. The stock’s 50-day moving average price is $4.09 and its 200 day moving average price is $4.71. Axsome Therapeutics has a 52-week low of $3.53 and a 52-week high of $9.11. The firm’s market capitalization is $123.93 million.
Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, May 9th. The company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by $0.01. On average, equities research analysts expect that Axsome Therapeutics will post ($1.41) EPS for the current year.
TRADEMARK VIOLATION WARNING: This article was originally reported by sleekmoney and is the property of of sleekmoney. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://sleekmoney.com/axsome-therapeutics-inc-axsm-lifted-to-sell-at-valuengine/1940647.html.
Large investors have recently modified their holdings of the company. Geode Capital Management LLC increased its stake in shares of Axsome Therapeutics by 9.8% in the first quarter. Geode Capital Management LLC now owns 57,803 shares of the company’s stock valued at $225,000 after buying an additional 5,156 shares during the last quarter. State Street Corp increased its stake in shares of Axsome Therapeutics by 6.7% in the fourth quarter. State Street Corp now owns 134,688 shares of the company’s stock valued at $908,000 after buying an additional 8,466 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Axsome Therapeutics during the first quarter valued at $121,000. SG Americas Securities LLC acquired a new stake in shares of Axsome Therapeutics during the first quarter valued at $139,000. Finally, Vanguard Group Inc. increased its stake in shares of Axsome Therapeutics by 23.0% in the first quarter. Vanguard Group Inc. now owns 334,745 shares of the company’s stock valued at $1,305,000 after buying an additional 62,556 shares during the last quarter. Hedge funds and other institutional investors own 32.93% of the company’s stock.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
To view ValuEngine’s full report, visit ValuEngine’s official website.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/axsome-therapeutics-inc-axsm-lifted-to-sell-at-valuengine/1940647.html
Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.